<DOC>
	<DOC>NCT00447005</DOC>
	<brief_summary>To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.</brief_summary>
	<brief_title>Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients histologically or cytologically diagnosed with advanced malignant solid tumors Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies Central lung lesions involving major blood vessels Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>PK</keyword>
	<keyword>Biomarker</keyword>
</DOC>